Table 1.
Baseline patient demographics and characteristics of COVID-19-positive inpatients treated with baricitinib/remdesivir/dexamethasone
| Characteristic | All Patients (n = 45) |
||
|---|---|---|---|
| Age—years | Mean age | 69.5 | ± 16.7 |
| Gender—no | Male | 21 | (46.7) |
| Female | 24 | (53.3) | |
| Ethnicity – no. (%) | Not Hispanic, Latino/a, or Spanish origin | 44 | (97.8) |
| Hispanic or Latino/a | 1 | (2.2) | |
| Race – no. (%) | White | 36 | (80.0) |
| Asian | 4 | (8.9) | |
| African American or Black | 2 | (4.4) | |
| Multiracial | 1 | (2.2) | |
| Declined | 2 | (4.4) | |
| Past medical history—no. (%) | Co-existing conditions: None | 1 | (2.2) |
| Co-existing conditions: One | 6 | (13.3) | |
| Co-existing conditions: Two or more | 38 | (84.4) | |
| Average body mass index | 31 | ||
| Body mass index ≥ 30 – no. (%) | 22 | (48.9) | |
| Body mass index ≥ 40 – no. (%) | 5 | (11.1) | |
| Hypertension | 19 | (42.2) | |
| Type 2 diabetes mellitus | 15 | (33.3) | |
| Hyperlipidemia | 11 | (24.4) | |
| Autoimmune disease (rheumatoid arthritis, psoriatic arthritis, Sjogren's Syndrome, Raynaud's phenomena, giant cell arteritis, ulcerative colitis or pemphigus vulgaris) | 8 | (17.8) | |
| Obstructive airway disease (asthma, chronic obstructive pulmonary disease, bronchiectasis or reactive airway disease) | 8 | (17.8) | |
| Obstructive sleep apnea | 7 | (15.6) | |
| Coronary artery disease | 6 | (13.3) | |
| Atrial fibrillation | 6 | (13.3) | |
| Heart failure (including: HFpEF, HFrEF or unspecified) | 4 | (8.9) | |
| Chronic kidney disease | 4 | (8.9) | |
| History of malignancy | 3 | (6.7) | |
| Aortic stenosis | 3 | (6.7) | |
| Osteoarthritis | 3 | (6.7) | |
| Pulmonary hypertension | 2 | (4.4) | |
| Average duration of symptoms prior to presentation – days | 6 | ||
| Average severity of illness at presentation | NEWS2 score | 5 | |
| WHO Clinical Status Score | 4 | ||
| Dose of Baricitinib—no. (%) | Baricitinib 4 mg daily or 2 mg twice daily | 34 | (75.6) |
| Less than baricitinib 4 mg daily or 2 mg twice daily | 11 | (24.4) | |
| Duration of Baricitinib—no. (%) | Less than 7 days – no | 22 | (48.9) |
| 7 days – no | 20 | (44.4) | |
| More than 7 days – no | 3 | (6.7) | |
| Average duration of baricitinib—(days) | 6.0 |
Plus–minus( ±) values are standard deviation. Patient race and ethnicity are self-reported by patient. Body mass index is calculated by weight (kilograms) divided by square of height (meters). Percentages may not total 100 because of rounding